Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
Bill to Nix Off-Year Scheme Politicized, Could Clear Lower House with Ishin Support
An opposition-backed bill to abolish “off-year” drug price revisions has increasingly taken on a political tone as potential support from the Japan Innovation Party (Nippon Ishin) will raise the likelihood of the legislation passing the lower chamber of the Diet.…
To read the full story
Related Article
- Japan’s Parliament Enacts Bill to Amend PMD Act
May 15, 2025
- Bill to Amend PMD Act Now in Upper House Deliberations
April 23, 2025
- Lower House Passes Bill to Amend PMD Act
April 21, 2025
- Lower House Health Committee OKs Bill to Amend PMD Act, Adopts Supplementary Resolution
April 17, 2025
- PMD Act Bill Set for Lower House Committee Vote on April 16
April 16, 2025
- Nippon Ishin Co-Leader Shows Understanding of Off-Year Price Revisions
April 11, 2025
- Diet Begins Deliberations on Amendment of PMD Act, Bill to Repeal Off-Year Scheme
April 7, 2025
- PMD Act Amendment to Enter Diet Debate; Parallel Deliberations Planned for Bill to Scrap Off-Year Revisions
April 3, 2025
- Opposition Parties Submit Bill to Scrap Off-Year Drug Price Revisions
December 23, 2024
- DPP to Co-Sponsor Bill to Make Drug Price Revisions a Biennial Event
December 18, 2024
- CDP OKs Bill to Scrap Off-Year Revisions, Aims for Diet Submission Soon
December 13, 2024
- Opposition CDP Eyes Nonpartisan Bill to Scrap Off-Year Drug Price Revisions
November 14, 2024
- Japan Political Parties Push Varied Pharma Policies as Election Campaign Kicks Off
October 15, 2024
REGULATORY
- Japan Govt Council Discusses Draft Recommendations for National MCM Strategy
December 9, 2025
- MHLW Eyes Govt-Led Ingredient Lists for Regional Formularies: LDP Briefing
December 9, 2025
- JMA Pushes Back on Incentives Tied to Regional Formularies: Chuikyo
December 9, 2025
- PMDA to Adopt General-Purpose AI in FY2025, Eyes Specialized Tools for Reviews and Safety Work
December 8, 2025
- Japan Likely to Extend Generic-Name Prescribing Premium to Biologics to Spur Biosimilars
December 8, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…